| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $85.13 | $197.65B | Uptrend |
Looking Through A Global Lens Part I: Probabilities And Opportunity In Japan
https://seekingalpha.com/article/4242782-looking-global-lens-part-probabilities-opportunity-japan?source=feed_tag_etf_portfolio_strategy
Feb 21, 2019 - It is a statistical fact that investors overweight their home country. For U.S. citizens, this is least detrimental since it's the highest weighted (~39%) globally. It is still inefficient, however.Wh
0
Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review
http://www.zacks.com/stock/news/355489/roches-rhhby-bla-for-lymphoma-drug-gets-priority-review?cid=CS-ZC-FT-355489
Feb 19, 2019 - The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
0
Teva Is Cheap And It Can Get Cheaper
https://seekingalpha.com/article/4242115-teva-cheap-can-get-cheaper?source=feed_tag_israel
Feb 19, 2019 - Since the acquisition of Actavis, Teva's balance sheet and cash flow were destroyed. It now has focused relentlessly on realigning its strategy and restoring the balance sheet.Halfway through now, it
0
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853
Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
0
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report
http://www.zacks.com/stock/news/354373/key-takeaways-from-eli-lillys-lly-q4-earnings-report?cid=CS-ZC-FT-354373
Feb 13, 2019 - Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
0
Top Research Reports for ExxonMobil, Merck & Danaher
http://www.zacks.com/research-daily/213347/top-research-reports-for-exxonmobil-merck-danaher?cid=CS-ZC-FT-213347
Feb 13, 2019 - Top Research Reports for ExxonMobil, Merck & Danaher
0
AbbVie Suffers Market Loss For Humira In Europe, But The U.S. Is A Different Story
https://seekingalpha.com/article/4240000-abbvie-suffers-market-loss-humira-europe-u-s-different-story?source=feed_sector_healthcare
Feb 11, 2019 - AbbVie missed its Q4 earnings expectations, but it does have many other products to help it get back on track in the coming quarters.The big loss for the quarter was due to international sales of Humi
0
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
http://www.zacks.com/stock/news/353654/is-a-disappointment-in-store-for-incyte-incy-q4-earnings?cid=CS-ZC-FT-353654
Feb 11, 2019 - Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
0
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-ZC-FT-353405
Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
0
Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition
https://seekingalpha.com/article/4239475-lilly-q4-looking-low-verzenio-sales-loxo-oncology-acquisition?source=feed_sector_healthcare
Feb 08, 2019 - Lilly's earnings fall in line with expectations, modest revenue beat from higher than anticipated performance in Mature Brands.Verzenio sales were much lower than expectations, reflecting competitive
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| MRK | Merck & Company, Inc. | NYSE | $70.42 | $187.28B |
| ABBV | AbbVie Inc. | NYSE | $95.37 | $144.42B |
| PFE | Pfizer, Inc. | NYSE | $43.01 | $252.13B |
| ABT | Abbott Laboratories | NYSE | $67.67 | $118.71B |
| NVO | Novo Nordisk A/S | NYSE | $47.64 | $114.84B |
NVS - Nasdaq
http://www.nasdaq.com/symbol/nvs
Quote information directly from the exchange
SEC filings
Comparison
Ownership
Insiders
Institutions
Revenue/EPS
Competitors
Guru
Report
Analysts
Pre-market
Quote
Consultant
After hours
Transcripts
NVS - Google Finance
https://www.google.com/finance?q=NVS
Industry related info and international coverage
Summary
News
NVS - Bloomberg
http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=NVS
Original news and commentary from Bloomberg
Charts
Financials with pensions
Snapshot
Earnings
Transactions
People
Options